I'm live-tweeting the afternoon discussion of the FDA's advisory committee meeting on $GRAL's blood test to detect multiple types of cancer. This is a very interesting screening test. It definitely identifies cancers. But there are a good number of people who do not have cancer who will get a positive result, and a lot of patients who will get a negative result who do have cancer. One really big question is whether it's really right to say this test identifies cancer "early." And even tougher one is how to think about a test that might make patients skip existing screening tests -- that could mean, for instance, that more breast or colorectal cancers might be missed. The public hearing was very interesting. Some speakers, like Phil Castle from NCI, worried about the false negatives. There were also patients who felt they had been saved by the results of the test. I'll be threading my notes from the afternoon here. Forgive me for typos -- these things move fast.

NEWS: Modified HIV drug reverses vision loss and paralysis in multiple sclerosis model. Read the full story ➡️ https://bit.ly/4rwr37x

CMS, along with @VP Vance's @WHFraudTF team, is taking concrete and strict action against those who defraud the American taxpayer. We're also ensuring our healthcare systems are protected — here's how: ➡️ We are preventing fraudulent and improper enrollments upfront. ➡️ We are removing existing unauthorized enrollments from the system and holding brokers accountable. ➡️ We are enforcing CMS regulations governing agents and brokers.

The Trump administration is delivering on its promise: faster approvals, more cures, stronger American biotech. The FDA approved a treatment for pancreatic cancer months ahead of schedule — doubling survival vs. chemo. https://www.washingtonexaminer.com/op-eds/4733623/pancreatic-cancer-fda-approval-rasonque-daraxonrasib-trump/

I’m following the FDA advisory committee on $GRAL’s Galleri blood test for detecting multiple types of cancer today and will be posting my thoughts here. So far, we’ve seen only company presentations, usually the dullest part of an advisory panel. But there have been some interesting tidbits. First, Grail is leaning heavily into simply the idea that they detect more cancers and can localize them, not getting into larger questions about the benefit to patients from doing so. See this slide. Speaking as part of Grail’s presentation, Mylynda Massart, a family medicine at UPMC, argued that the test can fit will with existing cancer screening and is something that many patients are eager to use. The panelists, in their first questions, expressed skepticism. One asked if the incredible, white-glove treatment that Grail gives doctors now can really scale. Another responded a Grail comment: “You’re carefully choosing your words. It is curative intent but you do not have outcome data.” Another panelist asked why the control arm of Grail’s randomized clinical trial in the UK was not included in the briefing document; the primary outcome of that trial was not included, either. Grail and FDA said that based on the agreement they came to with the FDA. Another panelist asked why so many patients from Grail’s other big study were not included in the briefing material; Grail said that had to do with when the data were submitted. What’s interesting is that the FDA seems to be telling the panel to limit the scope of its discussion. An FDA official said that both follow-ups and outcome data were beyond the scope of the claim being considered.